Clinical Impact of Liraglutide as a Treatment of Obesity

Heshma Alruwaili,1 Babak Dehestani,1 Carel W le Roux1,2 1Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland; 2Diabetes Research Group, School of Biomedical Sciences, Ulster University, Belfast, UKCorrespondence: Heshma Alruwaili Email alruwaily85@hot...

Full description

Bibliographic Details
Main Authors: Alruwaili H, Dehestani B, le Roux CW
Format: Article
Language:English
Published: Dove Medical Press 2021-03-01
Series:Clinical Pharmacology: Advances and Applications
Subjects:
Online Access:https://www.dovepress.com/clinical-impact-of-liraglutide-as-a-treatment-of-obesity-peer-reviewed-article-CPAA
_version_ 1818720974004027392
author Alruwaili H
Dehestani B
le Roux CW
author_facet Alruwaili H
Dehestani B
le Roux CW
author_sort Alruwaili H
collection DOAJ
description Heshma Alruwaili,1 Babak Dehestani,1 Carel W le Roux1,2 1Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland; 2Diabetes Research Group, School of Biomedical Sciences, Ulster University, Belfast, UKCorrespondence: Heshma Alruwaili Email alruwaily85@hotmail.comAbstract: Obesity is defined as a chronic, complex, relapsing disease characterized by excessive adipose tissue. Obesity impacts an individual’s health by increasing complications such as prediabetes, type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, metabolic syndrome, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD), cancers (eg endometrial), and obstructive sleep apnea (OSA). With the increase of obesity prevalence and its negative influences on individuals’ quality of life, there is a great need for therapy with a purpose to produce sustainable weight loss of more than 10% in order to improve or even reverse the progress of obesity related complications. The GLP-1 analogue, liraglutide reduce food consumption, promote weight reduction and improve metabolic functions. The primary mechanism of GLP-1 effect on food intake, metabolism, and weight reduction is mainly due to its actions on peripheral (vagal) and central pathways and activation of hindbrain and hypothalamus. The average weight reduction induced by liraglutide was significant and the weight loss was maintained as long as the patients on therapy. Liraglutide has advantages on weight loss maintenance and promoting cardiovascular disease (CVD) risk reduction, by decreasing systolic blood pressure and glycemic index. In this review, we aim to explain the mechanism of action of Liraglutide, its pharmacokinetic properties, its clinical impact on obesity and its safety and tolerability.Keywords: liraglutide, obesity, weight loss, GLP-1 analogue
first_indexed 2024-12-17T20:31:21Z
format Article
id doaj.art-a6dd020fdd0549d2a9e2f4e412d332e9
institution Directory Open Access Journal
issn 1179-1438
language English
last_indexed 2024-12-17T20:31:21Z
publishDate 2021-03-01
publisher Dove Medical Press
record_format Article
series Clinical Pharmacology: Advances and Applications
spelling doaj.art-a6dd020fdd0549d2a9e2f4e412d332e92022-12-21T21:33:34ZengDove Medical PressClinical Pharmacology: Advances and Applications1179-14382021-03-01Volume 13536063001Clinical Impact of Liraglutide as a Treatment of ObesityAlruwaili HDehestani Ble Roux CWHeshma Alruwaili,1 Babak Dehestani,1 Carel W le Roux1,2 1Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland; 2Diabetes Research Group, School of Biomedical Sciences, Ulster University, Belfast, UKCorrespondence: Heshma Alruwaili Email alruwaily85@hotmail.comAbstract: Obesity is defined as a chronic, complex, relapsing disease characterized by excessive adipose tissue. Obesity impacts an individual’s health by increasing complications such as prediabetes, type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, metabolic syndrome, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD), cancers (eg endometrial), and obstructive sleep apnea (OSA). With the increase of obesity prevalence and its negative influences on individuals’ quality of life, there is a great need for therapy with a purpose to produce sustainable weight loss of more than 10% in order to improve or even reverse the progress of obesity related complications. The GLP-1 analogue, liraglutide reduce food consumption, promote weight reduction and improve metabolic functions. The primary mechanism of GLP-1 effect on food intake, metabolism, and weight reduction is mainly due to its actions on peripheral (vagal) and central pathways and activation of hindbrain and hypothalamus. The average weight reduction induced by liraglutide was significant and the weight loss was maintained as long as the patients on therapy. Liraglutide has advantages on weight loss maintenance and promoting cardiovascular disease (CVD) risk reduction, by decreasing systolic blood pressure and glycemic index. In this review, we aim to explain the mechanism of action of Liraglutide, its pharmacokinetic properties, its clinical impact on obesity and its safety and tolerability.Keywords: liraglutide, obesity, weight loss, GLP-1 analoguehttps://www.dovepress.com/clinical-impact-of-liraglutide-as-a-treatment-of-obesity-peer-reviewed-article-CPAAliraglutideobesityweight lossglp-1 analogue
spellingShingle Alruwaili H
Dehestani B
le Roux CW
Clinical Impact of Liraglutide as a Treatment of Obesity
Clinical Pharmacology: Advances and Applications
liraglutide
obesity
weight loss
glp-1 analogue
title Clinical Impact of Liraglutide as a Treatment of Obesity
title_full Clinical Impact of Liraglutide as a Treatment of Obesity
title_fullStr Clinical Impact of Liraglutide as a Treatment of Obesity
title_full_unstemmed Clinical Impact of Liraglutide as a Treatment of Obesity
title_short Clinical Impact of Liraglutide as a Treatment of Obesity
title_sort clinical impact of liraglutide as a treatment of obesity
topic liraglutide
obesity
weight loss
glp-1 analogue
url https://www.dovepress.com/clinical-impact-of-liraglutide-as-a-treatment-of-obesity-peer-reviewed-article-CPAA
work_keys_str_mv AT alruwailih clinicalimpactofliraglutideasatreatmentofobesity
AT dehestanib clinicalimpactofliraglutideasatreatmentofobesity
AT lerouxcw clinicalimpactofliraglutideasatreatmentofobesity